Determination of plasma concentrations using Lc/ms and pharmacokinetics of ofloxacin in Patients with multi-drug resistant tuberculosis and In patients with multi-drug resistant tuberculosis co- Infected with hiv
| dc.contributor.advisor | Mugabo, Pirrie | |
| dc.contributor.author | Taha, Esraa | |
| dc.date.accessioned | 2022-11-09T11:48:08Z | |
| dc.date.accessioned | 2024-05-15T07:43:06Z | |
| dc.date.available | 2022-11-09T11:48:08Z | |
| dc.date.available | 2024-05-15T07:43:06Z | |
| dc.date.issued | 2009 | |
| dc.description | Magister Pharmaceuticae - MPharm | en_US |
| dc.description.abstract | Many studies have investigated the pharmacokinetics of anti-tuberculosis drugs in patients infected with tuberculosis. However, little is known about the pharmacokinetics of the drugs that are used in the treatment of multi-drug resistant tuberculosis (MDR- TB). Therefore, the objective of the present study was to investigate the steady state concentrations and the pharmacokinetics of ofloxacin, one of the drugs used in the treatment of MDR-TB in patients infected with MDR-TB and patients with MDR-TB co-infected with HIV Plasma samples were drawn at different times over 24 hours after ofloxacin oral administration. For the determination of ofloxacin plasma concentrations, the liquid chromatography coupled with mass spectrometry analysis method was used. | en_US |
| dc.identifier.uri | https://hdl.handle.net/10566/15190 | |
| dc.language.iso | en | en_US |
| dc.publisher | University of the Western Cape | en_US |
| dc.rights.holder | University of the Western Cape | en_US |
| dc.subject | Hiv | en_US |
| dc.subject | Mass spectrometry | en_US |
| dc.subject | Ofloxacin | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | Plasma levels | en_US |
| dc.title | Determination of plasma concentrations using Lc/ms and pharmacokinetics of ofloxacin in Patients with multi-drug resistant tuberculosis and In patients with multi-drug resistant tuberculosis co- Infected with hiv | en_US |